Lupus drug belimumab may shield organs from damage, new study hopes to prove

NCT ID NCT07056621

Recruiting now Disease control Sponsor: Biomedical Research Foundation, Academy of Athens Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is tracking 684 people with lupus to see if the drug belimumab can prevent serious organ damage (called BILAG A flares) better than standard care alone. Researchers are using real-world data from clinics in Greece, comparing patients on belimumab to those on usual treatments. The goal is to find out if belimumab changes the long-term course of lupus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belimumab
What this could lead to: If successful, this could show that belimumab helps prevent serious organ damage in lupus patients, supporting its use as a long-term disease control treatment.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also early-stage real-world evidence, not a definitive proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLE - SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

University Hospital 'Attikon'
RECRUITING

Athens, Attica, 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.